Login Register Cart 0
Perspective

The Marriage between Nanotechnology and Stem Cells Secretome for COPD

Author(s): Avinash Kharat, Avinash Sanap, Madhura Shekatkar, Supriya Kheur and Ramesh Bhonde*

Volume 23, Issue 7, 2022

Published on: 12 April, 2022

Page: [683 - 685] Pages: 3

DOI: 10.2174/1389450123666220318102138

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a disorder characterized by narrow alveoli as a result of emphysema. As such, there is no treatment to cure this disorder completely, and existing drugs only delay the progression of the disease. In recent years, the stem cell secretome as a drug is remarkably used as a regenerative therapy. In particular, cell-free therapy approaches offer great opportunities for the treatment of COPD. However, a few issues, such as the delivery of stem cell secretome as a drug to the alveolar region, have obstructed their application in clinical scales. To address these challenges, a combination of stem-cells secretome as a drug with nanotechnology could be a smart solution. We suggest that the combinational approach of delivering nanoparticles loaded with stem cell secretome could be a translational medicine approach for the successful outcome of COPD.

Keywords: Nanoparticles, mesenchymal stem cells, secretome, regenerative medicine, chronic obstructive pulmonary disease, drug delivery.

« Previous Next »
[1]
De Boer WI, Alagappan VKT, Sharma HS. Molecular mechanisms in chronic obstructive pulmonary disease: Potential targets for therapy. Cell Biochem Biophys 2007; 47(1): 131-47.
[PMID: 17406066]
[2]
Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. Am J Heal Pharm 2020; 77(4): 259-68.
[http://dx.doi.org/10.1093/ajhp/zxz306] [PMID: 31930287]
[3]
Candela M, Costorella R, Stassaldi A, Maestrini V, Curradi G. Treatment of COPD: The simplicity is a resolved complexity. Multidiscip Respir Med 2019; 14(1): 18.
[http://dx.doi.org/10.1186/s40248-019-0181-8] [PMID: 31171968]
[4]
Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-fernandez R. Mesenchymal stem cell secretome Toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 2017; 18(9): 1852.
[PMID: 28841158]
[5]
Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 2015; 219: 500-18.
[http://dx.doi.org/10.1016/j.jconrel.2015.07.024] [PMID: 26297206]
[6]
Rathod D, Kharat A, Wankhade V, Rai M. Nanotechnology the hope for new generation and its therapeutic applications. In: Rauta PR, Mohanta YK, Nayak D, Eds.Nanotechnology in Biology and Medicine 1st ed . Boca Raton: CRC 2019; pp. 159-65.
[http://dx.doi.org/10.1201/9780429259333-12]
[7]
Pokrovskaya LA, Zubareva EV, Nadezhdin SV, Lysenko AS. Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach. Res Results Pharmacol 2020; 6(1): 57-68.
[http://dx.doi.org/10.3897/rrpharmacology.6.49413]
[8]
Akram KM, Patel N, Spiteri MA, Forsyth NR. Lung regeneration : Endogenous and exogenous stem cell mediated therapeutic approaches. Int Mol scineces 2016; 17(1): 128.
[PMID: 26797607]
[9]
Asil SM, Ahlawat J, Barroso GG, Narayan M. Application of nanotechnology in stem-cell-based therapy of neurodegenerative diseases. Appl Sci (Basel) 2020; 10(14): 4852.
[http://dx.doi.org/10.3390/app10144852]
[10]
Kharat A, Patil VR, Kheur S, Bhonde R. Airway delivery of conditioned media from mesenchymal stem cells (MSC-CM) for COPD. Pulm Pharmacol Therauptics 2019; 58101832
[http://dx.doi.org/10.1016/j.pupt.2019.101832] [PMID: 31351137]
[11]
Kelsen SG. Animal models of chronic obstructive pulmonary disease (COPD). In: Inhalation Toxicology. Third Edition. 2014; pp. 339-56. In:
[12]
Ghorani V, Boskabady MH, Khazdair MR, Kianmeher M. Experimental animal models for COPD : a methodological review. 2017; 15: 25.
[http://dx.doi.org/10.1186/s12971-017-0130-2] [PMID: 28469539]
[13]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[14]
Passi M, Shahid S, Chockalingam S, Sundar IK, Packirisamy G. Conventional and nanotechnology based approaches to combat chronic obstructive pulmonary disease: Implications for chronic airway diseases. Int J Nanomedicine 2020; 15: 3803-26.
[http://dx.doi.org/10.2147/IJN.S242516] [PMID: 32547029]
[15]
J, Xu Y, Liu H, Song L. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease A review. J Nanobiotechnology 2020; 18: 1-25.
[http://dx.doi.org/10.1186/s12951-020-00703-5]
[16]
Malathi S, Nandhakumar P, Pandiyan V, Webster TJ, Balasubramanian S. Novel PLGA-based nanoparticles for the oral delivery of insulin. Int J Nanomedicine 2015; 10: 2207-18.
[PMID: 25848248]
[17]
Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: A review. Int J Mol Sci 2014; 15(4): 5852-73.
[http://dx.doi.org/10.3390/ijms15045852] [PMID: 24717409]
[18]
Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014; 2014180549
[http://dx.doi.org/10.1155/2014/180549] [PMID: 24772414]

Rights & Permissions Print Cite
Article Metrics
20
2
© 2024 Bentham Science Publishers | Privacy Policy